News

This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the company in lndonesla

The certification applies to the company’s Unit-II manufacturing facility located in Baddi, Himachal Pradesh

This recognition by USFDA strengthens Venus Remedies’ commitment to innovation in the fight against AMR

Under the terms of the agreement, the company will commence with a Phase I involving healthy volunteers in India, evaluating MET-X in combination with meropenem

The company has received GMP certification from Ministry of Health of Moldova

This authorization marks a significant milestone in the company’s journey to strengthen its presence in the high-growth Southeast Asian pharmaceutical market

The Board of Directors of the company at their meeting held on November 29, 2024 approved the same

This marks the first PIC/S GMP accreditation for Venus Remedies’ PFS facility

Its total volume of exports to Ukraine stands at $2.20 million

These approvals mark significant progress for Venus Remedies in expanding its market presence and providing access to critical medications for cancer patients in the region

The disbursement will bolster the company’s manufacturing capabilities and foster product diversification, including manufacturing of complex generics, in line with the vision of Atmanirbhar Bharat

These approvals signify its commitment to expanding its pharmaceutical portfolio and market presence

This strategic pivot marks R3SET’s foray into the wellness arena, coupled with the expansion of its pain management portfolio

Enoxaparin Sodium Injection, a low molecular weight heparin, effectively prevents blood clot enlargement and formation

To attain this prestigious Three Star status, a company must demonstrate a significant export performance, reaching a milestone of $100 million in a span of three years

The company has won Award in the esteemed ‘Excellence in Patient Safety and Care’ category

This remarkable milestone not only expands the pharma giant’s global presence but also underscores its commitment to advancing cancer care

With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 Countries

Additionally, the dossier has also been submitted in around 15 countries for getting the marketing authorisations

With this, the company has secured 511 marketing approvals for its oncology products across 66 countries

This registration with DSIR exemplifies Venus Remedies’ dedication to fostering innovation and making healthcare solutions more accessible

The company has an annual capacity of producing more than 5 million units of Enoxaparin, a widely used anticoagulant that prevents blood clots, at its robotic line

It is awaiting marketing authorization for the drug from another 16 countries

The company has extended its reach in the Association of Southeast Asian Nations region, South America and Eastern Europe

With this, it has secured 503 marketing approvals for its oncology products across 75 countries

The company has got this approval through its German subsidiary Venus Pharma GmbH

This international GMP approval, the 27th for Venus Remedies, will also enable the company to expand its product portfolio globally

The company has secures a marketing authorization from the largest market in the Gulf Cooperation Council region

With this, the number of international GMP certifications for Venus Remedies has gone up to 25

The company has consistently invested in research and development

The registration for Cisplatin will also expedite the process of registering the oncology products of Venus Remedies in many other countries

The company has received GMP certification for all its production facilities at its unit in Baddi, Himachal Pradesh

The company is expected to launch these drugs in the two countries in the next financial year

This is the fifth time and for the second consecutive year that the company has received this coveted recognition